机译:Lapatinib与Trastuzumab为Her2阳性早期乳腺癌(NeoAltto):一个随机的,开放标签,多方形,第3阶段试验
Massachusetts General Hospital Cancer Center Harvard Medical School Lawrence House 108 55 Fruit;
Frontier Science Scotland Kincraig United Kingdom Queen's University Belfast United Kingdom;
University Hospital Kiel Kiel Germany;
SOLTI Breast Cancer Research Group Barcelona Spain Breast Cancer Centre Vall d'Hebron;
Breast European Adjuvant Study Team Jules Bordet Institute Brussels Belgium;
Vall d'Hebron Institute of Oncology Barcelona Spain;
Instituto Nacional de Enfermedades Neoplásicas Lima Peru;
Breast International Group Jules Bordet Institute Brussels Belgium;
SOLTI Breast Cancer Research Group Barcelona Spain;
Breast European Adjuvant Study Team Jules Bordet Institute Brussels Belgium;
GlaxoSmithKline Collegeville PA United States;
European Institute of Oncology Milan Italy Swiss Centre for Breast Health Sant'Anna Clinics;
National Cheng Kung University Hospital Tainan Taiwan;
National Institute of Oncology Budapest Hungary;
Eastleigh Breast Care Centre Pretoria South Africa;
Institut Gustave Roussy Villejuif France;
Taipei Veterans General Hospital National Yang-Ming University Taipei Taiwan;
St Johannes Hospital Dortmund Germany;
Yonsei University College of Medicine Seoul South Korea;
Petrov Research Institute of Oncology St Petersburg Russian Federation;
Investigaciones Clínicas Ciudad Autónoma de Buenos Aires Buenos Aires Argentina;
Masarykuv Onkologicky Ustav Brno Czech Republic;
City Clinical Hospital Dnipropetrovsk Ukraine;
MD Anderson Cancer Center Houston TX United States;
Clinic for Gynaecology Gynaecologic Oncology and Obstetrics Breast Cancer Centre Charit;
Department of Biostatistics and Computational Biology Dana-Farber Cancer Institute Boston MA;
Department of Medicine Jules Bordet Institute Brussels Belgium;
机译:拉帕替尼联合曲妥珠单抗治疗HER2阳性早期乳腺癌(NeoALTTO):一项随机,开放标签,多中心,3期临床试验的生存结果及其与病理完全缓解的关系
机译:拉帕替尼联合曲妥珠单抗治疗HER2阳性早期乳腺癌(NeoALTTO):一项随机,开放标签,多中心,3期临床试验
机译:单独使用阿法替尼或阿法替尼加长春瑞滨与研究者选择曲妥珠单抗,拉帕替尼或两者同时治疗后发生进行性脑转移的HER2阳性乳腺癌的治疗选择(LUX-Breast 3):一项随机,开放标签,多中心,2期试验
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
机译:拉帕替尼与曲妥珠单抗对HER2阳性早期乳腺癌(NeoaLTTO):随机开放标记多中心3期临床试验
机译:Neoadjuvant Lapatinib的九年生存结果与胸瘤患者为Her2阳性乳腺癌(NeoAltto,Big 1-06):对多期,开放标签,第3期随机临床试验的最终分析。